TNF and colorectal carcinoma: IBD anti-inflammatories, such as anti-tumor necrosis factor-alpha (TNFα), improve IBD disease activity and can modulate the microbiome in a way that reduces the development of IBD-associated CRC (Yang et al., 2020).